# Lakefront Biotherapeutics NV clinical trials: 113 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 113 trials with Lakefront Biotherapeutics NV as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Lakefront Biotherapeutics NV: 113 rows for $5.65, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/lakefront-biotherapeutics-nv

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 113
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 113, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2024 | NCT06652633 | Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies | Lakefront Biotherapeutics NV | Phase 3 | Recruiting | Hematological Malignancies | 546 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06652633) |
| August 20, 2024 | NCT06561425 | A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma | Lakefront Biotherapeutics NV | Phase 1/2 | Terminated | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06561425) |
| September 21, 2023 | NCT06043739 | Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Bioavailability | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043739) |
| May 12, 2023 | NCT05856448 | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus | Lakefront Biotherapeutics NV | Phase 2 | Completed | Systemic Lupus Erythematosus | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05856448) |
| January 25, 2023 | NCT05695950 | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis | Lakefront Biotherapeutics NV | Phase 2 | Completed | Dermatomyositis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05695950) |
| July 29, 2022 | NCT05479058 | A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission | Lakefront Biotherapeutics NV | Phase 3 | Terminated | Ulcerative Colitis | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05479058) |
| April 19, 2022 | NCT05335447 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05335447) |
| March 9, 2022 | NCT05272683 | Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05272683) |
| September 1, 2021 | NCT05030857 | Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05030857) |
| July 26, 2021 | NCT04976270 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04976270) |
| July 21, 2021 | NCT04971746 | Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04971746) |
| May 28, 2021 | NCT04907149 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04907149) |
| April 23, 2021 | NCT04856358 | A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04856358) |
| February 3, 2021 | NCT04736927 | Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04736927) |
| January 22, 2021 | NCT04720183 | Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04720183) |
| January 13, 2021 | NCT04708184 | A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970 | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04708184) |
| January 12, 2021 | NCT04704739 | Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205 | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04704739) |
| January 7, 2021 | NCT04700280 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) | Lakefront Biotherapeutics NV | Phase 2 | Terminated | Primary Sjögren Syndrome | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04700280) |
| January 7, 2021 | NCT04700267 | A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus | Lakefront Biotherapeutics NV | Phase 1 | Terminated | Systemic Lupus Erythematosus | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04700267) |
| December 4, 2020 | NCT04653467 | A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects | Lakefront Biotherapeutics NV | Phase 1 | Completed | Healthy | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04653467) |
| October 20, 2020 | NCT04594928 | A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis | Lakefront Biotherapeutics NV | Phase 1 | Completed | Plaque Psoriasis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04594928) |
| October 8, 2020 | NCT04578548 | A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Lakefront Biotherapeutics NV | Phase 2 | Terminated | Autosomal Dominant Polycystic Kidney Disease | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04578548) |
| October 8, 2020 | NCT04577794 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis | Lakefront Biotherapeutics NV | Phase 2 | Completed | Ulcerative Colitis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04577794) |
| October 8, 2020 | NCT04577781 | A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid... | Lakefront Biotherapeutics NV | Phase 2 | Completed | Rheumatoid Arthritis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04577781) |
| October 5, 2020 | NCT04575818 | A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059 | Lakefront Biotherapeutics NV | Phase 1 | Terminated | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04575818) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 73 |
| Phase 1/2 | 1 |
| Phase 2 | 33 |
| Phase 3 | 6 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 96 |
| Terminated | 16 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 8 |
| Cystic Fibrosis | 8 |
| Colitis, Ulcerative | 4 |
| Idiopathic Pulmonary Fibrosis | 4 |
| Dermatitis, Atopic | 4 |
| Arthritis, Psoriatic | 3 |
| Crohn Disease | 3 |
| Osteoarthritis | 3 |
| Scleroderma, Systemic | 2 |
| Inflammatory Bowel Diseases | 2 |
| Spondylitis, Ankylosing | 2 |
| Autoimmune Diseases | 2 |
| Rheumatic Diseases | 2 |
| Lupus Erythematosus, Systemic | 2 |
| Psoriasis | 1 |
| Polycystic Kidney, Autosomal Dominant | 1 |
| Dermatomyositis | 1 |
| Lymphoma, B-Cell | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Burkitt Lymphoma | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
- [B2B outdoor advertising companies in the United States](https://specstream.ai/data/businesses/b2b-outdoor-advertising-companies/united-states)
- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Carpet cleaning companies in the United States](https://specstream.ai/data/businesses/carpet-cleaning-companies/united-states)
- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
